GlaxoSmithKline | GSK - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Alcon AG USD 31.62B 64M 2026-03
Almirall EUR 2.37B 29.97M 2026-06
Amgen USD 92.5B 1.92B 2026-03
argenx SE USD 10.03B 1.35B 2026-06
AstraZeneca USD 115.83B 1.82B 2026-06
Bayer EUR 107.94B 3.4B 2026-03
Biogen USD 32.09B 2.6B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Eli Lilly USD 116.58B 4.1B 2026-03
Fresenius EUR 41.4B 1.07B 2025-12
Fresenius Medical Care EUR 31.47B 465.26M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 61.74B 1.13B 2026-06
Glaxosmithkline GBP 62.87B 19.47B 2026-03
GRIFOLS EUR 20.08B 366M 2026-03
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Lakefront Biotherapeutics EUR 3.37B 34.09M 2026-03
Lonza CHF 18.97B 164M 2025-12
Merck EUR 53.07B 1.54B 2026-03
Merck USD 128.68B 8.18B 2026-03
Novartis USD 122.03B 3.5B 2026-06
Novo Nordisk DKK 559.22B 16.32B 2026-03
Orion EUR 1.87B 205.5M 2026-06
Pfizer USD 207.62B 542M 2026-03
Philips EUR 26.7B 565M 2026-06
Recordati EUR 5.33B 82.27M 2026-03
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Roche Holding CHF 98.2B 2.5B 2026-06
Sanofi EUR 129.06B 1.04B 2026-06
Smith & Nephew USD 10.69B 150M 2025-12
UCB EUR 18.16B 971M 2025-12